A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients

Potchavit Aphinives
Damnern Vachirodom
Chaiyut Thanapaisal
Dhanes Rangsrikajee
Ongart Somintara

Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand

Background: We previously studied the noninferiority of anastrozole (ANZ) versus ANZ followed by letrozole (A-LTZ) due to reimbursement policy. We found that patients with A-LTZ had better overall survival (OS) than did patients with ANZ alone. This study aimed to prove that patients with A-LTZ also had better OS than patients with letrozole (LTZ) alone.

Methods: All medical records of the breast cancer patients taking LTZ with or without ANZ between 2004 and 2013 were reviewed. All patients were divided into two groups: the LTZ group included patients treated with LTZ alone, and the A-LTZ group included patients treated with ANZ who were automatically changed to LTZ due to change of the reimbursement policy.

Results: From 359 cases, there were 179 cases in the LTZ group and 180 cases in the A-LTZ group. The mean age of patients in the LTZ group was 53.7 years and in the A-LTZ group was 54.2 years. The distribution of clinical stages among the LTZ group versus the A-LTZ group was 21 versus 4 (stage 1), 86 versus 116 (stage 2), 55 versus 46 (stage 3), and 17 versus 14 (stage 4), respectively. Among the LTZ patients, 63.7% took aromatase inhibitor monotherapy and 36.3% had a switching strategy, while in the A-LTZ group, 53.9% took AI monotherapy and 46.1% had a switching strategy. OS of the A-LTZ group was longer than that of the LTZ group.

Conclusion: The patients in A-LTZ, taking ANZ followed by LTZ had better OS than those in LTZ, taking LTZ alone.

Keywords: estrogen receptor-positive, hormonal responsive, tamoxifen

Introduction

One of the standard treatments for estrogen receptor-positive breast cancer patients is endocrine therapy. It can be used as an adjuvant for the early stage or a palliative for the advanced disease. In Thailand, the available oral antiestrogen drugs include tamoxifen, anastrozole (ANZ), letrozole (LTZ), and exemestane. For premenopausal patients, tamoxifen seems to be the drug of choice, while aromatase inhibitors (AIs) have been used for postmenopausal patients. AIs are divided into two groups: nonsteroidal, which includes ANZ and LTZ, and steroidal, which includes exemestane. A switching strategy using an AI and tamoxifen is as effective as the AI monotherapy.

In Thailand, some breast cancer patients receiving ANZ were automatically switched to LTZ due to the change of the reimbursement policy since 2008. We studied the outcome of this switching treatment to prove the noninferiority, but found that patients with ANZ followed by LTZ (A-LTZ) had better overall survival (OS) than patients with ANZ alone. Some studies have shown no difference in OS among AIs, either nonsteroidal or steroidal. Some cases changed from ANZ to LTZ due to early adverse effect of ANZ, but no clear superiority of LTZ was demonstrated. One study showed...
LTZ seemed to be superior to ANZ, but no clear benefit was demonstrated. From our previous study, we could not conclude whether A-LTZ was superior or similar to LTZ. So we designed the study comparing patients receiving LTZ and patients receiving A-LTZ during the same period.

Materials and methods

All medical records of the breast cancer patients taking LTZ between 2004 and 2013 were reviewed. AI therapy included two types of strategy: AI monotherapy for 5 years; or 2–3 years of tamoxifen followed by 2–3 years of AI, up to total of 5 years. All collected patients were divided into two groups: the LTZ group included patients taking LTZ with or without tamoxifen; and the A-LTZ group included patients taking ANZ who were automatically changed to LTZ, either in an AI monotherapy strategy or AI-tamoxifen switching strategy, due to the change of the reimbursement policy. Demographic data, type of reimbursement, endocrine therapy, and OS were reviewed and analyzed.

Demographic data was analyzed using Excel® 2007 (Microsoft Corp, Redmond, WA, USA). Survival data was analyzed using Stata version 10.1 (StataCorp LP, College Station, TX, USA). OS was analyzed using a Cox regression model and presented as Kaplan–Meier survival curve with a HR of 0.6824 (Figure 1), and the OS of the A-LTZ group was found to be significantly better than that of the LTZ group ($P=0.0386$). When the OS was stratified by each stage (Table 2), only stage 4 patients in the A-LTZ group had a significantly better OS than stage-matched patients in the LTZ group ($P=0.0114$); the Kaplan–Meier survival curve was shown, with a HR of 0.3083, in Figure 2.

Discussion

In Thailand, there are three major medical reimbursement systems: the Civil Servant Medical Benefit Scheme (CSMBS) for government officers, Social Security for employees, and non-CsMBs.

Table 1 Comparison of demographic data between the LTZ and the A-LTZ groups of patients

| Category                        | LTZ (n=179) | A-LTZ (n=180) |
|----------------------------------|-------------|---------------|
| Mean age (years)                 | 53.7±9.7    | 54.2±10.2     |
| Clinical staging                 |             |               |
| • Stage 1                        | 21 (11.73%) | 4 (2.22%)     |
| • Stage 2                        | 86 (48.04%) | 116 (64.44%)  |
| • Stage 3                        | 55 (30.73%) | 46 (25.55%)   |
| • Stage 4                        | 17 (9.50%)  | 14 (7.77%)    |
| Type of reimbursement            |             |               |
| • CSMBS                          | 89 (49.72%) | 83 (46.11%)   |
| • Non-CSMBS                      | 90 (50.28%) | 97 (53.89%)   |
| Endocrine treatment strategy     |             |               |
| • AI only                        | 114 (63.69%)| 97 (53.89%)   |
| • Stage 1                        | 18 (15.79%) | 2 (2.06%)     |
| • Stage 2                        | 60 (52.63%) | 59 (60.82%)   |
| • Stage 3                        | 32 (28.07%) | 29 (29.90%)   |
| • Stage 4                        | 4 (3.51%)   | 7 (7.22%)     |
| • AI + tamoxifen                 | 65 (36.31%) | 83 (46.11%)   |
| • Stage 1                        | 3 (4.62%)   | 2 (2.41%)     |
| • Stage 2                        | 26 (40.00%) | 57 (68.67%)   |
| • Stage 3                        | 23 (35.38%) | 17 (20.48%)   |
| • Stage 4                        | 13 (20.00%) | 7 (8.43%)     |
| Anastrozole duration (mean ± SD, months) |         |               |
| • All                            | 18.7±14.6   |               |
| • Stage 1                        | 24.2±18.6   |               |
| • Stage 2                        | 19.9±15.7   |               |
| • Stage 3                        | 18.4±14.4   |               |
| • Stage 4                        | 8.7±4.8     |               |

Abbreviations: AI, aromatase inhibitor; A-LTZ, anastrozole followed by letrozole; CSMBS, Civil Servant Medical Benefit Scheme (for government officers); LTZ, letrozole; SD, standard deviation.
Universal Coverage for all the remaining Thai people. On average, government officers have higher socioeconomic status than most Thai people. The proportions of CSMBS and non-CSMBS patients in the LTZ group (50:50) were higher than in the A-LTZ group (46:54). We classified the reimbursement systems into CSMBS and non-CSMBS because higher socioeconomic status might have a longer survival than lower socioeconomic status. In comparison, in our previous study, the proportions of CSMBS and non-CSMBS patients, respectively, in the ANZ group were nearly the same as those in the A-LTZ group (45:55 [ANZ] versus 46:54 [A-LTZ]). Although the OS of both the LTZ and ANZ groups differed significantly from the A-LTZ group, the HR of LTZ (0.6824) was higher than that of the ANZ (0.5515) group.

Some studies have reported the superiority of AI to tamoxifen but no significant difference in disease-free survival between the switching strategy compared with AI monotherapy strategy. However, AI produced more adverse events than tamoxifen, so we had to consider the survival benefit between the two strategies. The difference of HR between LTZ and ANZ groups might be affected by the proportions of AI monotherapy and switching strategy (64:36 versus 54:46).

This study confirmed that treatment with A-LTZ should lengthen the survival of hormone-sensitive breast cancer patients better than LTZ or ANZ. The efficacy of LTZ was shown to be the same as ANZ in several studies, although some studies have shown LTZ might be superior to ANZ in terms of quality of life, due to lower incidence of adverse events. But there were no data about sequential therapy of ANZ and LTZ. Both drugs were classified in the same group – nonsteroidal AI. So it seemed to be irrational using both drugs sequentially, even with their different chemical structure. We observed the shortest duration of ANZ usage with narrowest standard deviation in stage 4 patients of the A-LTZ group, which might relate to statistical significance in the OS difference between the two groups. However, this retrospective study with small number of patients can reach limited conclusions. Further prospective study with larger number of patients should be performed to confirm the better outcome of sequential therapy of ANZ and LTZ.

**Conclusion**

The patients in the A-LTZ group, taking A-LTZ, seemed to have better OS than those in the LTZ group, taking LTZ alone.
Disclosure
The authors report no conflicts of interest in this work.

References
1. Connor C, Attai D. Adjuvant endocrine therapy for the surgeon: options, side effects, and their management. *Ann Surg Oncol*. 2013;20(10):3188–3193.

2. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. *New Engl J Med*. 2003;348(24):2431–2442.

3. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M; Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. *Lancet Oncol*. 2009;10(11):45–53.

4. Cuzick J, Sestak I, Baum M, et al; ATAC/LATTE Investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. *Lancet Oncol*. 2010;11(12):1135–1141.

5. Davies C, Pan H, Godwin J, et al; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet*. 2013;381(9869):805–816.

6. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med*. 2003;349(19):1793–1802.

7. Jakobsen JS, Jonat W, Grant M, et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. *Lancet*. 2005;366(9484):455–462.

8. Burstein HJ, Prestrud AA, Seidenfeld J, et al; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. *J Clin Oncol*. 2010;28(23):3784–3796.

9. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. *Lancet*. 2011;377(9762):321–331.

10. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *N Engl J Med*. 2009;361(8):766–776.

11. Aphinives P, Vachirodom D, Thanapaisal C, Rangsrikajee D, Somintara O. Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy. *Breast Cancer (Dove Med Press)*. 2014;6:145–150.

12. Dixon JM, Renshaw L, Langridge C, et al. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. *Breast Cancer Res Treat*. 2011;125(3):741–749.

13. Riemsma R, Forbes CA, Kessels A, et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. *Breast Cancer Res Treat*. 2010;123(1):9–24.

14. Geisler J. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance? *Br J Cancer*. 2011;104(7):1059–1066.

15. Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled phase III trial. *J Clin Oncol*. 2013;31(11):1398–1404.

16. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype – ACOSOG Z1031. *J Clin Oncol*. 2011;29(17):2342–2349.

17. Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. *Int J Clin Pract*. 2007;61(12):2051–2063.

18. Beresford M, Tumur I, Chakrabarti J, Barden J, Rao N, Makris A. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. *Clin Oncol (R Coll Radiol)*. 2011;23(3):209–215.

19. Fontein DB, Seynaeve C, Hadji P, et al. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. *J Clin Oncol*. 2013;31(18):2257–2264.

20. Friese CR, Pini TM, Li Y, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. *Breast Cancer Res Treat*. 2013;138(3):931–939.
21. Berry J. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer. *Clin Ther*. 2005;27(11):1671–1684.
22. Thürlimann B, Keshaviah A, Coates AS, et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *N Engl J Med*. 2005;353(26):2747–2757.
23. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2011;103(17):1299–1309.
24. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. *J Clin Oncol*. 2004;22(21):4261–4271.
25. Thomas R. Examining quality of life issues in relation to endocrine therapy for breast cancer. *Am J Clin Oncol*. 2003;26(4):440–444.
26. Thomas R, Godward S, Makris A, Bloomfield D, Moody AM, Williams M. Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. *Clin Oncol (R Coll Radiol)*. 2004;16(7):485–491.